The analysis showed that DCT studies enable time and cost efficiencies at virtually every point in the trial process. Specifically, findings indicated that DCT studies could provide significant reductions in key trial issues, including time to first patient in (49%) and overall recruiting time (78%), and in protocol deviations (54%), screen failure rates (39%), and other concerns, thereby benefitting sponsor budgets and indicating enhanced patient engagement.
